Dermira and UCB Announce Start of Phase 3 Program for Cimzia® (Certolizumab Pegol) in Psoriasis

Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients (NASDAQ: DERM), and UCB, a global biopharmaceutical leader (Euronext: UCB), announced today that the first patients have been dosed in the Phase 3 clinical program designed to evaluate the efficacy and safety of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis. This is an important step forward in the collaboration between Dermira and UCB in the development of solutions for patients with moderate-to-severe plaque psoriasis, a severe autoimmune disease.1 CIMZIA® is not currently approved for the treatment of psoriasis by any regulatory authority worldwide.